Your Trusted Brand for Over 35 Years

Liver Degenerative Disease References

Disease Prevention and Treatment, 5th edition

The references on this page correspond with the print version of Disease Prevention and Treatment, 5th edition. Since we continuously update the protocols online in response to new scientific developments, readers are encouraged to review the latest versions of the protocols.

  1. NIDDK. Cirrhosis of the Liver 2000 Jan. NIH Publ. No. 00-1134. Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases/National Institutes of Health.
  2. AMA. The American Medical Association Encyclopedia of Medicine 1989. New York: Random House.
  3. Glanze, W.D., Ed. Mosby Medical Encyclopedia, Revised Edition 1996. St. Louis, MO: C.V. Mosby.
  4. Brewer, G.J., Fink, J.K., Hedera, P. Diagnosis and treatment of Wilson's disease. Semin. Neurol. 1999; 19(3): 261-70.
  5. Malik, A.H., Lee, W.M. Chronic hepatitis B virus infection: treatment strategies for the next millennium. Ann. Intern. Med. 2000 May 2; 132(9): 723-31.
  6. Lammert, F., Busch, N., Matern, S. Clinical aspects and therapy of viral hepatitis. Chirug 2000 Apr; 71(4): 381-8 (in German).
  7. Mayerat, C., Mantegani, A., Spertini, F., Frei, P.C. Mutations in the basal core promoter and precore/core gene of hepatitis B virus in patients with chronic active but not acute hepatitis B. Eur. J. Clin. Microbiol. Infect. Dis. 1999 Dec; 18(12): 871-8.
  8. Gumina, G., Song, G.Y., Chu, C.K. Advances in antiviral agents for hepatitis B virus. Antivir. Chem. Chemother. 2001; 12(Suppl. 1): 93-117.
  9. Ou, J.H.J. Viral hepatitis and its prevention. Infection Control Today Magazine 2002. Phoenix, AZ: Virgo Publishing.
  10. Glanze, W.D., Ed. Mosby Medical Encyclopedia, Revised Edition  1996. St. Louis, MO: C.V. Mosby.
  11. Braillon, A., Capron, J.P., Herve, M.A., Degott, C., Quenum, C. Liver in obesity. Gut 1985 Feb; 26(2): 133-9
  12. Day, C.P., Yeaman, S.J. The biochemistry of alcohol-induced fatty liver. Biochem. Biophys. Acta 1994 Nov 17; 1215(1-2): 33-48.
  13. Yang, S.Q., Lin, H.Z., Lane, M.D., Clemens, M., Diehl, A.M. Obesity increases sensitivity to endotoxin liver injury: implications for the pathogenesis of steatohepatitis. Proc. Natl. Acad. Sci. U.S.A. 1997 Mar 18; 94(6): 2557-62.
  14. Berson, A., De Beco, V., Letteron, P., Robin, M.A., Moreau, C., El Kahwaji, J., Verthier, N., Feldmann, G., Fromenty, B., Pessayre, D. Steatohepatitis-inducing drugs cause mitochondrial dysfunction and lipid peroxidation in rat hepatocytes. Gastroenterology 1998 Apr; 114(4): 764-74.
  15. Wallace, L.A., Pellizzari, E.D., Hartwell, T.D., Davis, V., Michael, L.C., Whitmore, R.W. The influence of personal activities on exposure to volatile organic compounds. Environ. Res. 1989 Oct; 50(1): 37-55.
  16. Vineis, P., Esteve, J., Terracini, B. Bladder cancer and smoking in males: types of cigarettes, age at start, effect of stopping and interaction with occupation. Int. J. Cancer 1984 Aug 15; 34(2): 165-70.
  17. Britton, R.S., Bacon, B.R. Role of free radicals in liver diseases and hepatic fibrosis. Hepatogastroenterology 1994 Aug; 41(4): 34-8.
  18. Feher, J., Vereckei, A., Lengyel, G. Role of free-radical reactions in liver diseases. Acta Physiol. Hung. 1992; 80(1-4): 351-61.
  19. Nidus. What are the primary treatments for cirrhosis? Well-Connected Report: Cirrhosis 1999 Mar. New York: Nidus Information Services (
  20. Takase, S., Matsuda, Y., Yasuhara, M., Takada, A. Effects of malotilate treatment on alcoholic liver disease. Alcohol 1989 May-Jun; 6(3): 219-22.
  21. Mirossay, L., Mojzis, J., Sallingova, Z. et al. Gastroprotective effect of malotilate in indomethacin- and ethanol-induced gastric mucosal damage. Physiol. Res. 1996; 45(5): 405-11.
  22. Ryhanen, L., Stenback, F., Ala-Kokko, L., Savolainen, E.R. The effect of malotilate on type III and type IV collagen, laminin and fibronectin metabolism in dimethylnitrosamine-induced liver fibrosis in the rat. J. Hepatol. 1996 Feb; 24(2): 238-45.
  23. NIDA. Hepatitis C. NIDA Community Drug Alert Bulletin 2002 Feb 21. Bethesda, MD: National Institute on Drug Abuse/National Institutes of Health/Department of Health and Human Services.
  24. Strickland, D.K. Hepatitis C. eMed. J. 2002 Jan 16 (
  25. Bergasa, N.V. Itching in Liver Disease 2002 Sep; New York: Columbia University.
  26. Chern, C.L., Huang, R.F., Chen, Y.H., Cheng, J.T., Liu, T.Z. Folate deficiency-induced oxidative stress and apoptosis are mediated via homocysteine-dependent overproduction of hydrogen peroxide and enhanced activation of NF-kappaB in human Hep G2 cells. Biomed. Pharmacother. 2001 Oct; 55(8): 434-42
  27. Fernandez, E., Pallini, R., Lauretti, L., La Marca, F., Sccgna, A., Rossi, G.F. Motonuclear changes after cranial nerve injury and regeneration. Arch. Ital. Biol. 1997 Sep; 135(4): 343-51.
  28. Rao, K.V., Qureshi, I.A. Reduction in the MK-801 binding sites of the NMDA sub-type of glutamate receptor in a mouse model of congenital hyper-ammonemia: prevention by acetyl-L-carnitine. Neuropharmacology 1999 Mar; 38(3): 383-94.
  29. Paradies, G., Petrosillo, G., Gadaleta, M.N., Ruggiero, F.M. The effect of aging and acetyl-L-carnitine on the pyruvate transport and oxidation in rat heart mitochondria. FEBS Lett. 1999 Jul 9; 454(3): 207-9.
  30. Garg, M.C., Bansal, D.D. Protective antioxidant effect of vitamins C and E in streptozotocin induced diabetic rats. Indian J. Exp. Biol. 2000 Feb; 38(2): 101-4.
  31. Mydlik, M., Derzsiova, K., Racz, O., Sipulova, A., Boldizsar, J., Lovasova, E., Hribikova, M. Vitamin E as an antioxidant agent in CAPD patients. Int. J. Artif. Organs 2002 May; 25(5): 373-8.
  32. Genova, M.L., Bonacorsi, E., D'Aurelio, M., Formiggini, G., Nardo, B., Cuccomarino, S., Turi, P., Pich, M.M., Lenaz, G., Bovina, C. Protective effect of exogenous coenzyme Q in rats subjected to partial hepatic ischemia and reperfusion. Biofactors 1999; 9(2-4): 345-9.
  33. Teranishi, M., Karbowski, M., Kurono, C., Nishizawa, Y., Usukura, J., Soji, T., Wakabayashi, T. Effects of coenzyme Q10 on changes in the membrane potential and rate of generation of reactive oxygen species in hydrazine- and chloramphenicol-treated rat liver mitochondria. Arch. Biochem. Biophys. 1999 Jun 1; 366(1): 157-67.
  34. Hazai, E., Monostory, K., Bakos, A., Zacher, G., Vereczkey, L. About paracetamol again. Orv. Hetil. 2001 Feb 18; 142(7): 345-9 (in Hungarian).
  35. Attri, S., Rana, S.V., Vaiphie, K., Katyal, R., Sodhi, C.P., Kanwar, S., Singh, K. Protective effect of N-acetylcysteine in isoniazid induced hepatic injury in growing rats. Indian J. Exp. Biol. 2001 May; 39(5): 436-40.
  36. Biewenga, G.P., Haenen, G.R., Bast, A. The pharmacology of the antioxidant lipoic acid. Gen. Pharmacol. 1997 Sep; 29(3): 315-31.
  37. Lykkesfeld, J. et al. Age-associated decline in ascorbic acid concentration, recycling, and biosynthesis in rat hepatocytes-reversal with R alpha lipoic acid supplementation. FASEB J. 1998; 12: 1183-9.
  38. Khanna, S., Atalay, M., Laaksonen, D.E. et al. Alpha-lipoic acid supplementation: tissue glutathione homeostasis at rest and after exercise. J. Appl. Physiol. 1999 Apr; 86(4): 1191-6.
  39. Sakaguchi, S., Iizuka, Y., Furusawa, S., Tanaka, Y., Takayanagi, M., Takayanagi, Y. Roles of selenium in endotoxin-induced lipid peroxidation in the rats liver and in nitric oxide production in J774A.1 cells. Toxicol. Lett. 200 Dec 20; 118(1-2): 69-77.
  40. Vouldoukis I, Lacan D, Kamate C, et al. Antioxidant and anti-inflammatory properties of a Cucumis melo LC. extract rich in superoxide dismutase activity. J Ethnopharmacol. 2004 Sep;94(1):67-75.
  41. Lester GE, Jifon JL, Crosby KM. Superoxide dismutase activity in mesocarp tissue from divergent Cucumis melo L. genotypes. Plant Foods Hum Nutr. 2009 Sep;64(3):205-11.
  42. Deulofeu, R., Pares, A., Rubio, M., Gasso, M., Roman, J., Gimenez, A., Varela-Moreiras, G., Caballeria, J., Ballesta, A.M., Mato, J.M., Rodes, J. S-Adenosylmethionine prevents hepatic tocopherol depletion in carbon tetrachloride-injured rats. Clin. Sci. 2000 Oct; 99(4): 315-20.
  43. Anon. Holistic Health Encyclopedia 2002. Oakford, PA: Telstar Innovations.
  44. Ma, X., Zhao, J., Lieber, C.S. Polyenylphosphatidylcholine attenuates non-alcoholic hepatic fibrosis and accelerates its regression. J. Hepatol. 1996 May; 24(5): 604-13.
  45. Lieber, C.S. Prevention and treatment of liver fibrosis based on pathogenesis. Alcohol Clin. Exp. Res. 1999 May; 23(5): 944-9.
  46. Pniachik, J., Baraona, E., Zhaoi, J., Lieber, C.S. Dilinoleoylphosphatidylcholine decreases hepatic stellate cell activation. J. Lab. Clin. Med. 1999 Apr; 133(4): 342-8.
  47. Wolf, D.C. Cirrhosis. eMed. J. 2001 Sep 6; 2(9) (
  48. Navender KP, Baraona E, Lieber CS. Polyenylphosphatidylcholine attenuates alcohol-induced fatty liver and hyperlipemia in rats. J Nutr. 1997;127(9):1800-6.
  49. Bosisio, E., Benelli, C., Pirola, O. Effect of the flavanolignans of Silybum marianum L. on lipid peroxidation in rat liver microsomes and freshly isolated hepatocytes. Pharmacol. Res. 1992 Feb-Mar; 25(2): 147-54.
  50. Valenzuela, A., Aspillaga, M., Vial, S., Guerra, R. Selectivity of silymarin on the increase of the glutathione content in different tissues of the rat. Planta Med. 1989 Oct; 55(5): 420-2.
  51. Sonnenbichler, J., Goldberg, M., Hane, L., Madubunyi, I., Vogl, S., Zetl, I. Stimulatory effect of silibinin on the DNA synthesis in partially hepatectomized rat livers: non-response in hepatoma and other malign cell lines. Biochem. Pharmacol. 1986a Feb 1; 35(3): 538-41.
  52. Sonnenbichler, J., Zetl, I. Biochemical effects of the flavonolignane silibinin on RNA, protein and DNA synthesis in rat livers. Prog. Clin. Biol. Res. 1986b; 213: 319-31.
  53. Shimazu, Y. An experimental and clinical study of energy-protein metabolism and host defense-repair mechanism in postoperative period-a significance of administration of branched chain amino acid. Nippon Geka Gakkai Zasshi 1990 Oct; 91(10): 1534-47 (in Japanese).
  54. Chalasani, N., Gitlin, N. Severe recurrent hepatic encephalopathy that responded to oral branched chain amino acids. Am. J. Gastroenterol. 1996 Jun; 91(6): 1266-8.
  55. Kato, M., Miwa, Y., Tajika, M., Hiraoka, T., Muto, Y., Moriwaki, H. Preferential use of branched-chain amino acids as an energy substrate in patients with liver cirrhosis. Intern. Med. 1998 May; 37(5): 429-34.